Paper
7 August 2019 Verteporfin Photodynamic therapy with 5 aza-deoxy-cytidine for neo-adjuvant treatment of primary breast cancer: Results of pre-clinical investigations
Author Affiliations +
Proceedings Volume 11070, 17th International Photodynamic Association World Congress; 1107097 (2019) https://doi.org/10.1117/12.2525337
Event: 17th International Photodynamic Association World Congress, 2019, Cambridge, Massachusetts, United States
Abstract
Primary breast cancer treatment relying on surgery with the use neo-adjuvant therapies has long been established treatment. Side effects from these and varying efficacy has lead to the search for novel therapies that may result in improved results. The use of Photodynamic therapy as a novel neo-adjuvant treatment alone and in combination with agents cytotoxic to breast cancer cells was investigated.
© (2019) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
S. M. Banerjee, P. Acedo, S. El Sheikh, A. Meecham, N. R. Williams, G. Gerrard, R. Hamoudi, A. J. MacRobert, and M. R. S. Keshtgar "Verteporfin Photodynamic therapy with 5 aza-deoxy-cytidine for neo-adjuvant treatment of primary breast cancer: Results of pre-clinical investigations", Proc. SPIE 11070, 17th International Photodynamic Association World Congress, 1107097 (7 August 2019); https://doi.org/10.1117/12.2525337
Advertisement
Advertisement
RIGHTS & PERMISSIONS
Get copyright permission  Get copyright permission on Copyright Marketplace
KEYWORDS
Photodynamic therapy

Breast cancer

Breast

Therapeutics

Tissues

Control systems

Flow cytometry

Back to Top